跳至主要内容
临床试验/JPRN-jRCT2080220900
JPRN-jRCT2080220900未知1 期

Safety and efficacy of TBI-0301 gene-transduced donor lymphocyte infusion in patients with hematological malignancy experiencing recurrence/relapse or aggravation after allogeneic hematopoietic stem-cell transplantation

Takara Bio Inc.0 个研究点目标入组 9 人开始时间: 2009年10月27日最近更新:
适应症

试验速览

阶段
1 期
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • (1)Patients with a diagnosis of relapse, recurrence or aggravation of hematological malignancy after related allogeneic stem cell transplantation
  • (2)Patients should be > 20 years old
  • (3)ECOG performance status (PS) 0 to 2
  • (4)No severe organ damage as measured by:
  • -Oxygen saturation > 93 % (non-invasive measurement is acceptable)
  • -AST (GOT) and ALT (GPT) < 5 X ULN
  • -Total bilirubin and serum creatinine < 3 X ULN
  • -Physically normal electrocardiogram
  • (1)Original donor of hematopoietic stem cell transplantation
  • (2)Donor should be > 20, < 65 years old
  • (3)ECOG performance status (PS) 0
  • (4)Having a good heart, lung, liver and kidney function
  • -No ischemic electrocardiographic changes and no arrhythmia requiring treatment on ischemic
  • -Chest x-ray without evidence of active infection, and arterial oxygen saturation > 93% without oxygen administration (non-invasive measurement is acceptable)
  • -Serum creatinine < 1.5 mg/dL
  • -AST (GOT) , ALT (GPT), and total serum bilirubin < 2 X ULN
  • (5)Having a good hematopoietic capacity
  • -WBC > 3,000 /microliter, PLT > 130,000 /microliter
  • -Hb > 13.0 g/dL for men, 11.0 g/dL for women

排除标准

  • (1)Relapsed, recurrent or aggravated patients in very early after transplantation who can not expect the effect of donor lymphocyte infusion.
  • (2)Patients with Epstein-Barr virus- associated lymphoproliferative disorder
  • (3)Presence of grade II to IV acute GVHD or extensive chronic GVHD
  • (4)LVEF at rest < 50 %
  • (5)Patients with central nervous system involvement
  • (6)Patients with multiple malignancies
  • (7)Patients with active infection
  • (8)Ongoing GCV, acyclovir or valacyclovir administration within 24 hours before the infusion of donor lymphocytes transduced with TBI-0301
  • (1)Presence of complication and medical history listed below:
  • -Autoimmune disease (include collagen disease)
  • -Phlebothrombosis, arteriosclerotic disease
  • -Congestive heart failure, ischemic Heart failure, cerebrovascular lesion
  • -Interstitial pneumonia
  • -Malignant tumor
  • (2)Diabetes uncontrollable even with regular insulin use, or uncontrollable hypertension
  • (3)History of grave drug allergy
  • (4)Pregnant or lactating women
  • (5)Any of the HBs antigen, HCV antibody and HIV antibody, and serological test for syphilis positivity
  • (6)Uncontrollable mental illness

研究者

相似试验